USA - NASDAQ:MDWD - IL0011316309 - Common Stock
The current stock price of MDWD is 17.49 USD. In the past month the price increased by 5.55%. In the past year, price increased by 4.61%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 51.11 | 781.23B | ||
JNJ | JOHNSON & JOHNSON | 18.61 | 448.07B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 15.09 | 262.92B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 19 | 261.56B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 14.88 | 254.99B | ||
MRK | MERCK & CO. INC. | 11.71 | 225.12B | ||
PFE | PFIZER INC | 8.03 | 154.70B | ||
SNY | SANOFI-ADR | 11.18 | 121.36B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 7.05 | 96.54B | ||
GSK | GSK PLC-SPON ADR | 10.09 | 91.68B | ||
ZTS | ZOETIS INC | 23.63 | 65.13B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 50.83 | 46.55B |
MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. ; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.
MEDIWOUND LTD
42 Hayarkon Street
YAVNE 8122745 IL
CEO: Sharon Malka
Employees: 111
Phone: 972779714100
The current stock price of MDWD is 17.49 USD. The price decreased by -2.94% in the last trading session.
The exchange symbol of MEDIWOUND LTD is MDWD and it is listed on the Nasdaq exchange.
MDWD stock is listed on the Nasdaq exchange.
12 analysts have analysed MDWD and the average price target is 31.28 USD. This implies a price increase of 78.85% is expected in the next year compared to the current price of 17.49. Check the MEDIWOUND LTD stock analysts ratings, price target forecast and up-and down grades for more detailed information.
MEDIWOUND LTD (MDWD) has a market capitalization of 190.29M USD. This makes MDWD a Micro Cap stock.
MEDIWOUND LTD (MDWD) currently has 111 employees.
MEDIWOUND LTD (MDWD) has a support level at 17.48 and a resistance level at 17.71. Check the full technical report for a detailed analysis of MDWD support and resistance levels.
The Revenue of MEDIWOUND LTD (MDWD) is expected to grow by 19.48% in the next year. Check the estimates tab for more information on the MDWD EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
MDWD does not pay a dividend.
MEDIWOUND LTD (MDWD) will report earnings on 2025-11-24.
MEDIWOUND LTD (MDWD) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.64).
The outstanding short interest for MEDIWOUND LTD (MDWD) is 12.37% of its float. Check the ownership tab for more information on the MDWD short interest.
ChartMill assigns a technical rating of 2 / 10 to MDWD. When comparing the yearly performance of all stocks, MDWD is a bad performer in the overall market: 71.74% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to MDWD. MDWD has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months MDWD reported a non-GAAP Earnings per Share(EPS) of -2.64. The EPS decreased by -22.22% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -41.72% | ||
ROE | -138.93% | ||
Debt/Equity | 0.4 |
12 analysts have analysed MDWD and the average price target is 31.28 USD. This implies a price increase of 78.85% is expected in the next year compared to the current price of 17.49.
For the next year, analysts expect an EPS growth of 8.58% and a revenue growth 19.48% for MDWD